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Background: Percutaneous transluminal angioplasty has been used with increasing frequency in the treatment of
infrainguinal arterial occlusive disease. This meta-analysis aimed to assess the middle-term outcomes after crural
angioplasty in patients with chronic critical limb ischemia and compare results with a meta-analysis of popliteal-to-distal
vein bypass graft.
Methods: Data were retrieved from 30 articles published from 1990 through 2006 (63% of articles published between
2000 and 2006). All studies used survival analysis, reported a 12-month cumulative rate of patency or limb salvage, and
included at least 15 infrapopliteal angioplasties. The outcome measures were immediate technical success, primary and
secondary patency, limb salvage, and patient survival. Data from life-tables, survival curves, and texts were used.
Results: The pooled estimate of success was 89.0% 2.2% for immediate technical result. Results at 1 and 36 months were
77.4% 4.1% and 48.6% 8.0% for primary patency, 83.3% 1.4% and 62.9%11.0% for secondary patency, 93.4%2.3%
and 82.4%  3.4% for limb salvage, and 98.3%  0.7% and 68.4%  5.5% for patient survival, respectively. Studies with
>75% of the limbs with tissue loss fared worse than their respective comparative subgroup for technical success and
patency but not for limb salvage or survival. No publication bias was detected.
Conclusion: The technical success and subsequent durability of crural angioplasty are limited compared with bypass
surgery, but the clinical benefit is acceptable because limb salvage rates are equivalent to bypass surgery. Further studies
are necessary to determine the proper role of infrapopliteal angioplasty. ( J Vasc Surg 2008;47:975-81.)Percutaneous transluminal angioplasty (PTA) has be-
come an acceptable form of treatment for patients with
infrainguinal arterial occlusive disease. Even in the setting
of chronic critical limb ischemia (CLI), broadly similar
outcomes have been obtained when PTA and bypass sur-
gery are compared.1 With PTA, local anesthesia can be
used, hospital stay is shorter, and morbidity and mortality
rates may be lower.2
In contrast with femoropopliteal PTA, infrapopliteal or
crural angioplasty PTA has been less frequently used, has
been offered predominantly to patients with CLI, has pro-
duced more heterogeneous results, and still remains con-
troversial.3-5 Formerly restricted to patients with short
stenotic lesions or to poor candidates for bypass surgery,6
crural PTA has been used in recent years preferentially over
bypass surgery by some groups.2 This wide scope of use, the
advent of new devices and techniques, the growing experi-
ence with endovascular therapy, and the competing interest
in traditional bypass surgery justify an assessment of crural
PTA. This meta-analysis of studies of crural PTA performed
in patients with CLI aimed to estimate the middle-term
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doi:10.1016/j.jvs.2008.01.005patency and limb salvage, to investigate the relationship
between these outcomes, and compare results with a meta-
analysis of popliteal-to-distal vein by-pass graft.
METHODS
Study identification. Articles published from January
1981 through October 2006 in the MEDLINE and
Excerpta Medica Database (EMBASE) databases were
searched. The descriptors used to find titles of possible
interest were “infrapopliteal angioplasty,” “below knee an-
gioplasty,” “crural angioplasty,” and “tibial angioplasty.”
After reading the abstracts online, 70 articles were printed
for complete reading. Articles referenced were read selec-
tively, and the systematic review finally included 30 arti-
cles.2-31 These selected articles covered a period from 1990
to 2006, 19 (63%) were published from 2000 to 2006, 5
(16%) from 1995 to 2000, and 6 (20%) between 1990 and
1995 (Appendix, online only.)
Criteria for inclusion. The articles included satisfied
the following criteria: (1) aminimumof 15 crural PTAs, (2)
a greater number of these procedures than femoropopliteal
PTAs, when both were described together, (3) most pa-
tients with ischemic rest pain or tissue loss, (4) use of
survival analysis to describe outcomes, and (5) a minimum
follow-up of 12 months, at least for some patients. Al-
though authors from two centers reported more than one
study on the subject,9,20-22 care was taken not to include
any PTA more than once. Studies with incomplete data of
demographic or clinical variables were not excluded (Table I).
Outcomes. The outcomes selected for meta-analysis
included immediate technical success, primary and second-
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mended in The Society for Vascular Surgery/International
Society for Cardiovascular Surgery A Hoc Subcommittee
on Reporting Standards for Endovascular Procedures.32
Primary patency reflects the fate of a single PTA procedure,
and secondary patency reflects the fate of initial and subse-
quent PTA procedures altogether. Continued clinical or
hemodynamic success was occasionally used as a surrogate
for patency. Limb salvage and patient survival as outcomes
of major importance were also studied.
Data extraction. We retrieved the data from life-tables
and from survival curves that showed the number of crural
PTAs, limbs, or patients at risk for all intervals. We also
retrieved the data from texts and less complete survival
curves, combined data from the text with a life-table or
survival curve to generate data for a different outcome, and
reviewed the data extracted from each study.
Comparison with bypass grafting surgery. A recent
meta-analysis of popliteal-to-distal vein bypass grafts was
used as a comparator meta-analysis.33 This study used
methods similar to those of the current meta-analysis and
targeted the same population of patients. The median of
the average age was 70 years, and the median prevalence
rate was 72% for male sex, 86% for diabetes mellitus, 88%
for tissue loss, and 19% for renal failure. Patency and limb
salvage, but not patient survival, were estimated (Table II).
The difference between secondary and primary patency was
1.6% and 4.4% at 1 and 36 months, respectively, whereas
the difference between limb salvage and secondary patency
was 0.2% and 5.6%.
Study quality. An ideal study should report the pe-
riod of study, the rate of patients requiring crural PTA, the
number of patients, limbs and procedures, the number of
more proximal procedures, the clinical symptoms, the
periprocedural complications (either procedural or non-
procedural), the rate and causes of early death, life-tables
rather than graphs, the 1-month follow-up interval, an
account for loss to follow-up, and the rates of technical
Table I. Demographic and clinical variables for 30
studies conducted between 1990 and 2006
Variablesa Original series Studies with no data
Patients 2557
Limbs 2653
Procedures 2693
Mean age 70 (64-81) 5
Male sex 60 (40-84) 7
Hypertension 54 (16-88) 11
Diabetes mellitus 61 (13-100) 5
Renal failure 23 (10-100) 16
Smoking 50 (15-97) 17
Heart disease 58 (22-83) 11
Cerebrovascular disease 14 (7-26) 18
Occlusive lesion 41 (0-100) 7
Tissue loss 76 (11-100) 7
aValues are medians (range), except for patients, limbs, procedures, and
results for studies with no data.success, primary and secondary patency, limb salvage, andpatient survival. Of particular relevance is a link between
predictive variables and each life-table. Other relevant items
are the rate of tissue loss, the regimen of postoperative
antithrombotic therapy, data on further bypass, and the
absence of a flat tail in the survival curves for patency and
limb salvage. Hence, a perfect study would score 21, with a
decrease of 1 point for each unmet requirement. No blind-
ing process was used when the studies were scored for
quality.
Subgroup meta-analysis. The studies were sub-
grouped according to the proportion of limbs with tissue
loss, the extension of the crural PTA, and the use of
subintimal dissection. The assumption was made that tissue
loss and limb salvage were associated and that studies that
described crural PTA alone or subintimal angioplasty alone
included more homogenous patients (Table III). There-
fore, meta-analysis of such subgroups could be compared
with both the meta-analysis of other subgroups and the
comparator meta-analysis.
Sensitivity analysis. Complementary analyses aimed
to quantify the effects of immediate technical success, to
determine the contribution of repeat crural PTA in main-
taining patency, and to explain why so many failed angio-
plasties did not lead to major amputation. Because several
studies failed to report all of the outcomes of interest,
specific subsets of studies that measured any two outcomes
under comparison were used to further investigate the
relationship between technical success and primary patency
(n  15), between secondary and primary patency (n 
11), and between limb salvage and secondary patency (n 9).
To explore the relationship between limb salvage and
secondary patency, not considered as salvaged were the
limbs with persisting CLI, the limbs that received a success-
ful bypass  1 month, and 25% of the limbs in diabetic
patients in whom pain at rest could be a manifestation of
painful diabetic neuropathy rather than truly ischemic rest
pain.34 Sensitivity analysis also excluded studies that in-
cluded patients with claudication, scored the lowest for
quality, used surrogates for primary patency, came from
nonvascular services, or contained only patients with renal
failure (Table IV). Finally, a funnel plots graph investigated
publication bias (Fig 1).
Statistical methods. The meta-analysis combined
monthly hazard rates from single series to yield a pooled
estimate of success for each month of follow-up. The
product of successive monthly pooled estimates of success
then yielded a pooled measure of success for each outcome
and a standard error was calculated for this measure at
several intervals. Between-study variances calculated as pre-
viously reported were used to reduce the influence of study
size on the pooled estimates.35 The differences between
groups (Table II) and subgroups (Table III) were assessed
statistically with a method that judges the significance of
differences by examining the overlap between confidence
intervals and does not calculate P values.36 A random-
effects model of meta-analysis was preferred because pa-
tients, vascular specialists, and quality of care likely differ
worldwide.
tes 
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Characteristics of the original studies. Most of the
30 studies included targeted the population of patients
with CLI generally (n  24), but a few studies targeted
diabetic patients (n  2), patients with end-stage renal
disease (n  2), and poor candidates for bypass (n  2).
The mean age and the rates of male gender, hypertension,
and diabetes mellitus were often reported, but most studies
Table II. Meta-analysis results of crural percutaneous tran
Result 1 month 6 months
Primary patency
PTA 77.4  4.1 65.0  7.0
Bypass 93.3  1.1 85.8  2.1
P .05 .05
Secondary patency
PTA 83.3  1.4 73.8  7.1
Bypass 94.9  1.0 89.3  1.6
P .05 .05
Limb salvage
PTA 93.4  2.3 88.2  4.4
Bypass 95.1  1.2 90.9  1.9
Patient survival
PTA 98.3  0.7 92.3  5.5
Bypass NA NA
NA, Estimates not available; PTA, percutaneous transluminal angioplasty.
aValues are pooled estimate and standard error.
Table III. Subgroup meta-analysis of early death, technic
Variable
Early death,
median
Technical success,
%
Prim
All 1.8 89.0  2.2 58.
Tissue loss
75% 2.0 83.6  3.0 52.
75% 1.3 93.3  1.5 66.
P .05
Crural PTA
Alone 0.6 88.7  4.8 52.
Combined 2.0 88.4  2.6 58.
Subintimal dissection
Routinely 0.6 83.9  2.7 55.
Other 2.0 90.3  2.7 58.
PTA, Percutaneous transluminal angioplasty.
aOutcomes were estimated from different studies. Values are pooled estima
Table IV. Sensitivity analysis for primary patency and
limb salvagea
Reason for study exclusion
Primary
patency, %
Limb
salvage, %
Contained patients with claudication 0.3 1.8
One outlier in the funnel graph 2.0 2.9
Surrogates for patency 1.3 . . .
Nonvascular services 0.1 0.2
All patients with renal failure . . . 0.1
All above simultaneously 1.7 1.7
aValues are changes in the 36-month pooled estimates.omitted the rates of smokers and patients with renal failure(Table I). Tissue loss and diabetes correlated moderately
(n  23, r  0.63, P  .002), but no other important
association was found in a correlation matrix of study
Fig 1. Inverted funnel graph shows one outlier (gray circle) whose
exclusion increases the 12-month pooled estimate of limb salvage
from 86% (black vertical line) to 89% (gray vertical line). Symmetry
for study size50 does not indicate the presence of publication bias.
inal angioplasty and popliteal-to-distal bypassa
1 year 2 years 3 years
58.1  4.6 51.3  6.6 48.6  8.0
81.5  2.0 76.8  2.3 72.3  2.7
.05 .05 .05
68.2  5.9 63.5  8.1 62.9  11.0
85.9  1.9 81.6  2.3 76.7  2.9
.05
86.0  2.7 83.8  3.3 82.4  3.4
88.5  2.2 85.2  2.5 82.3  3.0
87.0  2.1 74.3  3.7 68.4  5.5
NA NA NA
cess, and 12-month outcomesa
tency, Secondary patency,
%
Limb salvage,
%
Patient survival,
%
.6 68.2  5.9 86.0  2.7 87.0  2.1
.0 55.8  5.2 86.1  3.8 85.3  3.8
.3 74.0  8.0 92.6  2.3 87.3  2.6
.05
1.8 74.0  8.5 85.2  5.5 85.7  4.5
.0 60.9  5.8 86.8  3.2 86.0  2.7
2.1 70.9  11.4 88.7  4.8 81.4  4.2
.9 66.0  7.1 84.8  3.3 87.7  1.9
standard error.slumal suc
ary pa
%
1  4
5  5
0  5
0  1
1  5
9  1
0  4variables. At least 141 of 2653 limbs (5.3%) did not have
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113), acute arterial occlusion (n  18), or a failing graft
(n 10). In21 studies, themost frequently treated artery was
the tibioperoneal trunk (n 8), the anterior tibial (n 9),
the peroneal (n  4), or was not specified (n  9). Of the
19 studies published since January 2000, only five reported
the TransAtlantic Inter-Society Consensus classification of
arterial lesions.37
The study design was retrospective in 26 of the 30
studies reviewed, of which eight came from United States
and 22 from 11 European countries. Outcomes for primary
a secondary patency, or both, were reported in 23 studies,
and seven omitted patency. With respect to limb salvage,
the number of articles that contributed at least one series to
the meta-analysis was 25 initially and at 12 months, 17 at
24 months, and 10 at 36 months. Twenty-four studies
(80%) reported the number of subsequent bypass grafts,
but only 10 (33%) measured runoff. Nine studies used
balloon angioplasty only, whereas the other 21 reported
some technical peculiarities, which included subintimal an-
gioplasty routinely (n 7) or occasionally (n  4), stents
(n  3), atherectomy (n  3), endografts (n  1), throm-
bolytic therapy (n 1), or a combination of these (n 2).
Overall, three crural PTAs alone were done for each crural
PTA combined with a proximal PTA. The median score of
study quality was 15 (range, 5-18), whereas the more
common study defect was not using life-tables (n 24) and
not reporting the secondary patency (n  22), the total
number of PTA procedures (n  20), and the losses to
follow-up (n  16).
Complications. In a total of 21 studies with 1743
crural PTAs, 136 (7.8%) procedure-related complications
were reported. These included groin hematoma (n  55),
thrombosis (n 37), embolism (n 17), perforation (n
13), dissection (n  2), graft rupture (n  1), false aneu-
rysm (n  5), gastrointestinal hemorrhage (n  4), and
unspecified complications (n  2). Surgery other than
amputation was required to treat the foregoing complica-
tions in 22 instances. Fifteen nonprocedural complications
reported in five studies with 903 patients included nonfatal
myocardial infarction, heart failure, or cardiac arrhythmia in
10, and azotemia in 5.
Main outcomes. The pooled estimate of immediate
technical success was 89.0%  2.2% overall. The corre-
sponding estimate was 91.4%  1.8% for 16 of the 22
studies of primary patency, 90.2%  2.9% for 10 of the 12
studies of secondary patency, and 85.0%  2.8% for 20 of
the 25 studies of limb salvage. The middle-term estimates
of primary patency, secondary patency and limb salvage
were assessed reliably until 36 months (Fig 2).
In 14 studies primary patency was defined in a standard
fashion, but nine other reported clinical or hemodynamic
success only, which was used in the current study as a
surrogate for primary patency, and seven did not report
patency at all. No association was found between 12-month
primary or secondary patency and any demographic or
clinical variable. The pooled estimate of primary failure was
22.6% at 1 month, 2.4% to 5.8% from 2 to 6 months, and2.7% from 7 to 36 months. Eight studies reported sec-
ondary patency in a standard fashion, three reported clinical
success, and one reported tertiary patency, which measures
the joint effect of repeated attempts at revascularization of
any type. The pooled estimate of secondary failure was
16.7% 1 month, 1.1% to 4.3% from 2 to 6 months, and
2.3% from 7 to 36 months. The corresponding pooled
estimates of patency were significantly worse than those
estimated in the comparator meta-analysis (Table II).
The pooled estimate of amputation was 6.6%within the
first month, 1.9% in the second month, 0.5% to 1.4% from
3 to 6 months, and was 0.8% from 7 to 36 months. The
corresponding pooled estimates of limb salvage tended to
be worse than those estimated in the comparator meta-
analysis, but the difference was not significant (Table II).
Limb salvage at 12 months correlated moderately with
tissue loss (n  21, r  0.60, P  .004).
The median early mortality rate calculated for the data
from 23 studies was 1.8%. In 10 studies with 1140 patients,
18 early deaths were attributed to complications of surgery
(amputation in 2; bypass in 1), 8 to heart disease, and 7 to
other causes, whereas 7 reported no early deaths for 228
patients, 6 did not discriminate the causes of 14 early deaths
for 400 patients, and 7 omitted mortality information for
789 patients. Patient survival at 12months correlatedmod-
erately with renal failure (n 11, r0.70, P .02), but
was not associated with immediate technical success. The
causes of late deaths in the studies reviewed were not
reported with sufficient detail.
Subgroup meta-analysis. Subgroups did not differ
significantly in patient survival and limb salvage at 1 and 12
months (Table III). The immediate technical success and
the primary patency were significant better in the subgroup
with 75% of the limbs with tissue loss. Patency and limb
salvage results were slightly better for studies that used
crural PTA combined with more proximal PTAs and for
studies that used subintimal dissection routinely. In the
Fig 2. Meta-analysis estimates of primary patency (black line),
secondary patency (gray line), limb salvage (red line).latter studies, the inferior estimates of both technical suc-
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estimates of 12-month limb salvage (Table III).
Sensitivity analysis. Of the 176 primary failures 1
month, 74 (42%) were immediate failures. When the results
of the meta-analysis that included all available studies were
contrasted with those obtained in the meta-analysis of
specific subgroups, the difference between secondary and
primary patency decreased from 5.9% to 2.0% at 1 month
and from 14.3% to 9.4% at 36 months. The difference
between secondary patency and patency increased from
10.1% to 11.7% at 1 month and decreased from 19.5% to
18.9% at 36 months. When the concept of early limb
salvage excluded the limbs with persisting CLI or a success-
ful bypass 1 month and the limbs with a hypothetical
painful diabetic neuropathy, the difference between limb
salvage and secondary patency in the specific subgroup of
studies decreased from 11.7% to 6.4% at 1 month and from
18.9% to 13.3% at 36 months. Finally, the pooled estimate
of primary patency and limb salvage changed by3% at 36
months when selective exclusion of studies was done (Table
IV), and the inverted funnel graph showed one outlier
whose exclusion improved symmetry (Fig 1).
DISCUSSION
Low rates of early mortality have been alleged in favor
of crural PTA in the management of CLI. The early death
rate was slightly lower than that in the comparator meta-
analysis (median, 1.8% vs 2.1%), but such rate may be
higher when crural PTA is used as part of a PTA-first
strategy. In this setting, Haider et al2 recently reported an
early mortality rate of 2.7% with the preferential use of
infrainguinal PTA. In this current study, the procedure-
related morbidity of 7.7% was tolerable when taking into
account that surgical intervention other than amputation
was done in 1.6% only.
The immediate technical failures of crural PTAs con-
tributed 42% of the primary failures1month, whereas the
primary patency estimates decreased at lower rates beyond
that time. Of interest was that immediate technical failure
limb salvage at 1 month correlated moderately, but such
biologically plausible cause-and-effect association does not
conform to the commonly held opinion that a failed at-
tempt at crural PTA can be treated successfully with repeat
crural PTA and does not harm subsequent attempts at
bypass grafting.3,9,7,20,22 Anyway, decreasing the rate of
immediate technical failure is the key to improve patency
Table V. Average difference (gap) between pooled estima
Studies Outcome No.
All Primary patency 22
Secondary patency 12
Subgroups Primary patency 11
Secondary patency 11and limb salvage. Clearly, this will depend on the develop-ment ofmore effective endovascular procedures and also on
a better selection of cases, but these conditions may not be
compatible each other. For example, subintimal dissection
has extended the use of crural PTA for long occlusive
lesions at the expenses of inferior rates of technical success.
Also as a consequence of high rates of technical failure,
the pooled primary patency of 77.4% at 1 month for crural
PTA did not match the pooled primary patency of 93.3% in
the comparator meta-analysis.33 Repeat attempts at PTA
after immediate failure or loss of patency represent an
advantage over repeat bypass grafting, which is trouble-
some and not always feasible, but such advantage has not
been measured precisely. In the current overview, the rela-
tionship between primary and secondary patency was mea-
sured by using all available studies initially and by using a
special subset of 15 studies in a second step (Table V). In
the latter, the difference between secondary and primary
patency of 11.7% at 36 months exceeded the difference of
4.4% in the comparator meta-analysis. By definition, this
reflected the advantage of repeat crural PTA over revision
bypass surgery in the maintenance of patency. Likewise, the
difference between limb salvage and secondary patency of
about 19% at 36 months exceeded by far the difference of
5.6% in the comparator meta-analysis.
Of interest was that the disparity between limb salvage
and secondary patency was noted earlier in the first month
and increased slowly thereafter; One should therefore pay
attention to the preoperative conditions and perioperative
events when trying to explain that disparity.With regards to
preoperative conditions, there were fewer limbs with tissue
loss and fewer diabetic patients than in the comparator
meta-analysis. The studies reported that patients with fewer
limbs with tissue loss not only fared better for limb salvage
but also for the other outcomes, possibly because of less
advanced arterial disease. In addition, limbs with rest pain
require less complete revascularization to avert CLI and to
avoid amputation. Although diabetic patients with tissue
loss are in greater danger of amputation, diabetic patients
with pain at rest in their lower extremities do not always
have truly limb-threatening ischemia38 but rather painful
diabetic neuropathy, a condition that afflicts 25% of this
population but does not jeopardize limb viability.34
Three main factors may have influenced the wide gap
between limb salvage and secondary patency:
● CLI persisted after crural PTA failure, but a proximal
ntil 36 months
1 Outcome No. Gap 2
Secondary patency 12
% 18.0%
Limb salvage 26
Secondary patency 9
% 21.9%
Limb salvage 9tes u
Gap
10.9
7.6PTA remained patent.39
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number of amputations. Indeed, in the nine studies
that described both limb salvage and secondary pa-
tency, there were 157 secondary losses of patency but
only 56 amputations, thus leaving 82 losses to be
explained. Because there were at least 114 crural PTAs
combined to a more proximal PTA and at least 25
subsequent bypasses, the joint effect of these proce-
dures can explain the magnitude of Gap 2 (Table V), at
least in part.
● Possibly not all patients had truly limb-threatening
ischemia.38 Despite the loss of patency, these hypo-
thetical patients could have remained with mild rest
pain or small ulcers indefinitely or could have amputa-
tion delayed.
The growing experience, the many technical refine-
ments of PTA—notably subintimal dissection—and the
continuous improvement in limb salvage found in the
cumulative meta-analysis justify the prospect of better out-
comes for crural PTA in the near future. As a reflection of
the state of the art, Haider et al2 recently reported an early
death rate of 2.7% for 166 angioplasty (67%) and 80 bypass
patients (33%) in the femoropopliteal axis and 32 angio-
plasty (28%) and 82 (72%) bypass patients in the infrapop-
liteal area, whereas additional attempts at revascularization
after PTA failure included more bypasses than PTA proce-
dures. These data indicate that the crural PTA-first strategy
is not necessarily safer, is of limited use, and complements
rather than replaces bypass surgery. Amputation-free sur-
vival and the quality of life for strictly comparable patients
have shown no difference between a PTA-first strategy and
a bypass-first strategy, but the latter has been more costly.1
The current study has several limitations attributable to
shortcomings in the existing literature combined with the
nonrestrictive criteria of inclusion adopted. First, because
in several studies of small size the follow-up time was
naturally short, only a few studies were available for the
meta-analysis of middle-term outcomes. Second, the sub-
grouping of studies did not separate patients with or with-
out tissue loss completely and included fewer studies in the
subgroup of both crural PTA alone and in the subgroup of
subintimal angioplasty. Third, some topics could not be
properly addressed, notably the relationship between tech-
nical failure, further intervention, and the fate of the index
limb. Finally, some attractive features of crural PTA could
not be addressed at all, namely the use of local anesthesia,
the avoidance of surgical incision, a shorter length of hos-
pital stay, patients’ preferences, the impact on costs, and the
use of a crural PTAwith low chance of success faced with an
imminent major amputation.
Internal and external validity of the inferences from this
meta-analysis seem supported. The studies were reviewed
in sufficient number, used data of acceptable quality, and
reported high response rates, whereas the systematic review
used an inclusive set of entry criteria compatible with real
life. Subgroup meta-analysis showed that a low proportion
of tissue loss and crural PTA combined to proximal PTAintroduced a measurable bias in favor of crural PTA com-
pared with the meta-analysis of surgical bypasses (Table
III). Finally, sensitivity analysis mitigated other limitations
by excluding several studies for different reasons and by
creating a scenario to explain the disparity between limb
salvage and secondary patency.
CONCLUSION
Despite comparison of crural PTA with bypass grafts
that shows better primary and secondary patency than with
open surgical procedures, limb salvage is comparable be-
tween the two series and shows the potential of PTA for
treating CLI. The choice of this therapeutic method as an
initial option or not during patient’s treatment demands
experience and judgment from the surgical team. The ideal
situation is the one where surgical teams that are tradition-
ally involved with limb salvage operations and distal bypass
get experience with PTA practice. This universe of medical
practice is wide. Although PTAs can be repeated, they are
not innocuous. Some urgent situations can result as a
failure of attempted PTA, and a surgical bypass grafting
may be required. On the other hand, surgical bypass may
benefit from endovascular technology, from the operation
to the postoperative period, as these techniques are more
and more involved in bypass-saving procedures. Elucida-
tion of the proper role of crural PTA requires further
studies.
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First author Patients Limbs Diabetes, (%
Haider2 32 32 NA
Kudo3 52 52 NA
Boyer4 49 49 73.5
Parsons5 66 66 NA
Spinosa6 40 44 60.0
Wölfle7 84 89 88.1
Marzelle8 23 23 76.0
Vraux9 36 40 72.2
Treiman10 25 25 48.0
Brosi11 29 38 60.0
Aulivola12 79 90 78.0
Sigala13 52 52 100
Brillu14 37 37 48.6
Brown15 40 40 63.6
Bull16 168 168 52.4
Danielsson17 140 155 57.1
Favre18 24 25 50.0
Löfberg19 82 86 74.4
Ingle20 77 77 46.0
Vraux21 46 50 60.9
Nydahl22 27 28 33.0
Tisi23 51 51 NA
Söder24 60 72 76.7
Barton25 43 NA 51.2
Lazaris26 24 24 NA
Sivananthan27 38 41 13.2
Faglia28 564 564 100
Bosiers29 443 443 44.0
Schwarten30 96 112 62.5
Ascher31 30 32 73.0
NA, Data not available; PTA, percutaneous transluminal angioplasty.l studies reviewed
) Tissue loss, % Crural PTAs Combined PTA, %
NA 32 NA
NA 52 NA
59.2 49 NA
NA 66 0
90.9 50 58.0
94.4 89 0
87.0 25 36.0
77.5 40 20.0
24.0 25 0
NA 38 52.6
100 90 31.1
76.9 52 0
64.9 37 51.4
NA 55 0
36.3 168 34.5
62.6 155 76.1
54.2 25 0
89.4 92 59.8
51.9 79 0
92.0 50 0
85.7 28 67.9
NA 51 25.5
90.3 72 NA
NA 48 47.9
NA 24 41.7
10.5 50 88.0
82.5 564 26.8
19.9 443 NA
76.0 112 6.3
50.0 32 87.5
